FMP
NASDAQ
11.1 USD
0.34 (3.06%)
Dr. Saurabh Saha M.D., Ph.D.
Healthcare
Biotechnology
https://www.centessa.com
NASDAQ
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and ...
0001847903
US1523091007
152309100
1 Ashley Road
44 203 9206789
GB
75
May 28, 2021
0001847903
NASDAQ
Biotechnology
Healthcare
152309100
US1523091007
GB
11.1
1.37
408.9k
1.08B
-
3.52-12.45
3.47
-
-
-
-
-6.73
-
https://www.centessa.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.